KASA BIO is a molecular diagnostics company developing a proprietary high multiplex probe technology for the targeted detection of nucleic acid biomarkers.
Our vision is to provide simple and inexpensive solutions for diagnosis of complex diseases using well adopted PCR technology.
Founders have extensive experience in molecular biology and molecular diagnostics.
Diagnostic Challenges
Various infectious and oncological diagnostic applications require analysis of multiple DNA or RNA biomarkers.
Lack of availability of a quantitative multiplex platform for analysis of gene expression and miRNA signature analysis.
Lack of availability of a tool for analysis of multiple biological specimens at resource limited setting.
Requirement of larger sample volume for multi-biomarker analysis.
Our Solution
A novel high multiplex probe technology to expand the capacity of qPCR, digital PCR systems and
isothermal amplification systems.
A technology for synchronous or asynchronous and quantitative or qualitative analysis of multiple
DNA or RNA biomarkers including miRNAs.
A multiplexing technology independent of melt curve analysis or amplitude modulation.
Technology measures unutilized/depleted probes and differentiates different classes of
unutilized/depleted probes labelled with identical fluorescence moiety.
News
KASA BIO’s core technology has received US Patent.
KASA BIO has received SBIR Phase 1 Awards from NIH.
